iifl-logo

Venus Remedies Ltd Balance Sheet

Add as a Preferred Source on Google
₹1,725
(-3.96%)
Oct 1, 2026|12:19:58 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2026Mar-2025Mar-2024Mar-2023

Equity Capital

13.37

13.37

13.37

13.37

Preference Capital

0

0

0

0

Reserves

676.26

576.13

495.22

464.68

Net Worth

689.63

589.5

508.59

478.05

Minority Interest

Debt

12.41

0

38.68

38.68

Deferred Tax Liability Net

18.95

22.99

28.78

43.43

Total Liabilities

720.99

612.49

576.05

560.16

Fixed Assets

265.98

240.53

223.85

225.77

Intangible Assets

Investments

237.75

84.24

19.24

20.27

Deferred Tax Asset Net

4.61

7.4

17.86

32.78

Networking Capital

184.61

202.32

247.46

228.01

Inventories

129.37

100.49

117.81

113.6

Inventory Days

Sundry Debtors

116.39

99.26

89.54

84.92

Debtor Days

Other Current Assets

98.53

110.7

123.18

111.02

Sundry Creditors

-110.77

-68.6

-51.74

-48.95

Creditor Days

Other Current Liabilities

-48.91

-39.53

-31.33

-32.58

Cash

28.03

77.99

67.64

53.3

Total Assets

720.98

612.48

576.05

560.13

Venus Remedies : related Articles

Venus Remedies Secures Ukrainian GMP Certification for Baddi Facility

The Unit-II Baddi plant, which got the renewed certification, has state-of-art infrastructure and state-of-the-art manufacturing technology to cater to complex therapeutic segments in an efficient manner. 

22 May 2025|12:41 PM
Read More
Venus Remedies Secures Key Approvals, Strengthens Global Market Reach

The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.

31 Dec 2024|09:16 PM
Read More
Venus Remedies gets approval for pre-filled syringe facility

Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.

6 Nov 2024|10:36 AM
Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.